-+ 0.00%
-+ 0.00%
-+ 0.00%

CERVOMED INC - PLANS TO INITIATE PHASE 3 TRIAL EVALUATING NEFLAMAPIMOD IN PATIENTS WITH DLB IN THE SECOND HALF OF 2026

Reuters·05/18/2026 11:30:00

Please log in to view news